Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
Sara Lonardi, MD
Advertisement
Sara Lonardi, MD, is chief of the Oncology 3 Unit of Veneto Institute of Oncology (IOV) – IRCCS.
Articles by Sara Lonardi, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
JNJ-6143 Elicits PSA Responses in Heavily Pretreated mCRPC
2
Chidamide Plus Nivolumab Shows Potential Frontline Role in Melanoma
3
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
4
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
5